Related Experiment Video

Updated: Apr 27, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

9.2K

Cardiac concerns associated with strontium ranelate

Jean-Yves Reginster1

  • 1University of Liège, Department of Public Health, Epidemiology and Health Economics , CHU Sart-Tilman, 4020 Liège , Belgium +32 4270 3257 ; +32 4270 3253 ; jyreginster@ulg.ac.be.

Expert Opinion on Drug Safety
|July 15, 2014
PubMed

Insights

Strontium ranelate effectively reduces osteoporosis fractures. However, randomized controlled trials show an increased myocardial infarction (MI) risk, which is mitigated by excluding patients with cardiovascular contraindications.

Area of Science:

  • Osteoporosis treatment
  • Cardiovascular safety of medications

Background:

  • Strontium ranelate is effective in reducing vertebral and non-vertebral fractures in osteoporosis patients.
  • Cardiac safety concerns have led to contraindications for strontium ranelate in patients with specific cardiovascular conditions.

Purpose of the Study:

  • To evaluate the cardiac safety of strontium ranelate.
  • To assess the risk of myocardial infarction (MI) associated with strontium ranelate treatment.

Main Methods:

  • Literature search and data collection from the European Medicines Agency.
  • Analysis of randomized controlled trial (RCT) data on MI incidence.
  • Review of observational studies from real-life medical practice.

Main Results:

  • RCTs showed a higher incidence of non-adjudicated MI with strontium ranelate versus placebo (1.7% vs 1.1%).
  • No increase in cardiovascular mortality was observed.
  • Excluding patients with cardiovascular contraindications mitigated the MI risk (OR: 0.99).
  • Observational studies in real-life settings did not report a cardiac safety signal.

Conclusions:

  • Increased cardiac event risk with strontium ranelate detected in RCTs, but not in real-world data.
  • Excluding patients with cardiovascular contraindications effectively controls MI risk.
  • Strontium ranelate remains a viable option for severe osteoporosis patients without cardiovascular contraindications who cannot tolerate other treatments.
Abstract

Keywords:
cardiac safetymyocardial infarctionosteoporosisstrontium ranelate

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
484
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
936
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K